Avastic wasn't only rejected by the FDA because of its lack of efficacy; there were some serious side effects, as well. Read this interesting summary of the risks associated with the drug.

How could the FDA panel reject a drug that helps to slow the spread of cancer? This nice article helps make sense of the research results and the FDA's decision.

While it rejected Avastin for breast cancer treatment, the FDA recently approved Ixempra for treatment of advanced breast cancer. Find out more about Ixempra and how it works here.

Genetech, the company that makes Avastin, has other breast cancer studies in the works. This is an interesting article that explains why Avastin might just be approved in the future.

Although the FDA panel rejected Avastin for breast cancer treatment, it is an approved drug for other cancers. Learn more about how Avastin works here.

The FDA panel rejected Avastin for breast cancer treatment not because the drug was completely ineffective, but because it didn't do enough. Read the results of the clinical trial here.

An FDA panel didn't recommend Avastin for breast cancer treatment because the drug didn't increase survival rates. Get the details here.

Even without FDA approval, the cost of Avastin could be prohibitive for women who want to use it to slow the growth of their breast cancers. Is it worth $100,000 a year?

While Avastin was rejected for breast cancer, doctors currently employ many treatment approaches for battling breast cancer. Find out what options exist.